Physician profile
Laura Leon
NPI 1619593126
$883.22
in general payments reported to CMS, 2019-2025
13 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $92.48 · 2024: $385 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $212.46 | 2024-2025 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $172.36 | 2023-2025 | |
| Novo Nordisk INC | $134.40 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $98.15 | 2023-2025 | Verquvo |
| Lilly USA, LLC | $62.84 | 2024-2025 | Mounjaro, Zepbound |
| Sanofi Pasteur INC. | $42.67 | 2024-2025 | |
| Janssen Biotech, INC. | $38.07 | 2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.41 | 2024 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $23.88 | 2023 | Inpefa |
| Janssen Pharmaceuticals, INC | $18.62 | 2024 | Xarelto |
| Xeris Pharmaceuticals, INC. | $18.26 | 2025 | Keveyis |
| Glaxosmithkline, LLC. | $17.94 | 2024 | Shingrix, Arexvy |
| Organon LLC | $13.16 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.